Pharsight

Descovy patents expiration

DESCOVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(1 year, 19 days from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(2 years ago)

US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(1 year, 6 months from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

Descovy is owned by Gilead Sciences Inc.

Descovy contains Emtricitabine; Tenofovir Alafenamide Fumarate.

Descovy has a total of 7 drug patents out of which 1 drug patent has expired.

Expired drug patents of Descovy are:

  • US7803788

Descovy was authorised for market use on 04 April, 2016.

Descovy is available in tablet;oral dosage forms.

Descovy can be used as treatment of hiv infection; prophylaxis of hiv-1 infection; treatment of hiv-1 infection, treatment of hiv-1 infection, prophylaxis of hiv-1 infection; treatment of hiv-1 infection; treatment of hiv infection.

The generics of Descovy are possible to be released after 15 February, 2033.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 7, 2029

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 04 April, 2016

Treatment: Treatment of hiv-1 infection; Prophylaxis of hiv-1 infection; Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of DESCOVY before it's drug patent expiration?
More Information on Dosage

DESCOVY family patents

Family Patents